tailieunhanh - Báo cáo khoa học: Engineering toxins for 21st century therapies

‘Engineering Toxins for 21st Century Therapies’ (9–10 September 2010) was part of the Royal Society International Seminar series held at the Kavli International Centre, UK. Participants were assembled from a range of disciplines (academic, industry, regulatory, public health) to discuss the future potential of toxin-based therapies. | IFEBS Journal MEETING REPORT Engineering toxins for 21st century therapies John A. Chaddock1 and K. Ravi Acharya2 1 Syntaxin Limited Abingdon Oxon UK 2 Department of Biology and Biochemistry University of Bath UK Keywords biotechnology botulinum neurotoxin innovation therapy toxin Correspondence K. R. Acharya Department of Biology and Biochemistry University of Bath Claverton Down Bath BA2 7AY UK Fax 44 1225 386779 Tel 44 1225 386238 E-mail bsskra@ J. A. Chaddock Syntaxin Limited Units 4-10 Barton Lane Abingdon Oxon OX14 3YS UK Fax 44 1235 552200 Tel 44 1235 552115 E-mail Received 5 November 2010 revised 21 December 2010 accepted 10 January 2011 Engineering Toxins for 21st Century Therapies 9-10 September 2010 was part of the Royal Society International Seminar series held at the Kavli International Centre UK. Participants were assembled from a range of disciplines academic industry regulatory public health to discuss the future potential of toxin-based therapies. The meeting explored how the current structural and mechanistic knowledge of toxins could be used to engineer future toxin-based therapies. To date significant progress has been made in the design of novel recombinant biologics based on domains of natural toxins engineered to exhibit advantageous properties. The meeting concluded firstly that future product development vitally required the appropriate combination of creativity and innovation that can come from the academic biotechnology and pharma sectors. Second that continued investigation into understanding the basic science of the toxins and their targets was essential in order to develop new opportunities for the existing products and to create new products with enhanced properties. Finally it was concluded that the clinical potential for development of novel biologics based on toxin domains was evident. doi Introduction It is a paradox of drug development that nature s most .